Leman Biotech Lausanne SA is a spin-off company of EPFL co-founded by Prof. Li Tang, Head of the Laboratory of Biomaterials for Immunoengineering at the Swiss Federal Institute of Technology Lausanne (EPFL). With headquarters in Shenzhen (China), Leman Biotech recently closed an angel financing round of US$11 million and aims to develop and commercialize new metabolic cancer immunotherapies. The company combines its core technology of immunometabolic reprogramming (Meta 10) with artificial intelligence (AI) to develop next-generation tumor immunotherapy drugs. Leman Biotech's current R&D pipelines consist of metabolism-enhanced CAR-T cell therapy and a biomacromolecule drug pipeline. Recently, Leman Biotech entered the clinical stage with initiation of IIT clinical trials for its metabolically armed CAR-T cell therapy. In Switzerland, the company has established a new drug discovery center in Biopole and plans to initiate clinical trials for its cell-based immunotherapy pipeline.